1. Zdravotnická ročenka České republiky 2013. ÚZIS ČR: Praha 2014. ISBN 978–80–7472–135–9.
2. Go AS, Mozaffarian D, Roger VL et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation 2013; 127(1): e6-e245. Dostupné z DOI: <http://doi:10.1161/CIR.0b013e31828124ad>.
3. Go AS, Mozaffarian D, Roger VL et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation 2014; 129(3): e28-e292. Dostupné z DOI: <http://doi: 10.1161/01.cir.0000441139.02102.80>.
4. Report of the Second Task Force on Blood Pressure Control in Children – 1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics 1987; 79(1): 1–25.
5. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control. Results from the Health Survey for England 1998. Hypertension 2001; 38(4): 827–832.
6. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an age-old debate. Hypertension 2008; 51(4): 952–959.
7. Cífková R, Bruthans J, Adámková V et al. Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006–2009. Studie Czech post-MONICA. Cor Vasa 2011; 53(4–5): 220–229.
8. Keyhani S, Scobie JV, Hebert PL et al. Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits. Hypertension 2008; 51(4): 1149–1155.
9. Gu Q, Burt VL, Paulose-Ram R et al. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999–2004. Am J Hypertens 2008; 21(7): 789–798.
10. Olsen H, Klemetsrud T, Stokke HP et al. Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway. Blood Press 1999; 8(2): 94–101.
11. Wassertheil-Smoller S, Anderson G, Psaty BM et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women’s Health Initiative. Hypertension 2000; 36(5): 780–789.
12. Oparil S. Women and hypertension: what did we learn from the Women’s Health Initiative? Cardiol Rev 2006; 14(6): 267–275.
13. Journath G, Hellénius ML, Manhem K. Hyper-Q Study Group, Sweden. Association of physician’s sex with risk factor control in treated hypertensive patients from Swedish primary healthcare. J Hypertens 2008; 26(10): 2050–2056.
14. Laughlin GA, Barret-Connor E, Kritz-Silverstein D et al. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 2000; 85(2): 645–651.
15. Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 2004; 43(5): 918–923.
16. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273(3): 199–208.
17. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses’ health study; a prospective, observational study. Ann Intern Med 2001; 135(1): 1–8.
18. Falkenborn M, Persson I, Terent A et al. Hormone replacement therapy and the risk of stroke, follow-up of a population-based cohort in Sweden. Arch Intern Med 1993; 153(10): 1201–1209.
19. Finucane FF, Madans JH, Bush TL et al. Decreased risk of stroke among postmenopausal hormone users, results from a national cohort. Arch Intern Med 1993; 153(1): 73–79.
20. Scuteri A, Bos AJG, Brant LJ et al. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann Intern Med 2001; 135(4): 229–238.
21. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280(7): 605–613.
22. Rossouw JE, Anderson GL, Prentice RL et al. Writing Group of Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321–333.
23. Farquhar CM, Marjoribanks J, Lethaby A et al. Cochrane HT Study Group. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005; (3):CD004143. Dostupné z DOI: <http://dx.doi.org/10.1002/1465868.CD004143.pub2>.
24. Mosca L, Benjamin EJ, Berra K et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the American Heart Association. Circulation 2011; 123(11): 1243–1262. Erratum in Circulation. 2011; 123(22): e624. Circulation. 2011; 124(16): e427.
25. Melloni C, Berger JS, Wang TY et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 2010; 3(2): 135–142.
26. Turnbull F, Woodward M, Neal B et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 2008; 29(21): 2669–2680.
27. Gueyffier F, Boutitie F, Boissel JP et al. The INDANA Investigators. The effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. Results from a meta-analysis of individual patient data randomised controlled trials. Ann Inter Med 1997; 126(10): 761–767.
28. Wing LM, Reid CM, Ryan P et al. Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348(7): 583–592.
29. Zanchetti A, Julius S, Kjeldsen S et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens 2006; 24(11): 2163–2168.
30. Klungel OH, De Boer A, Paes AHP et al. Sex differences in the pharmacological treatment of hypertension: a review of population-based studies. J Hypertens 1997; 15(6): 591–600.
31. Lewis CE. Characteristics and treatment of hypertension in women: a review of the literature. Am J Med Sci 1996; 311(4): 193–199.
32. Cauley JA, Cummings SR, Seeley DG et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The study of Osteoporotic Fractures Research Group. Ann Intern Med 1993; 118(9): 666–673.
33. Lewis CE, Grandits GA, Flack J et al. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension Study. Arch Intern Med 1996; 156(4): 377–385.
34. August P, Oparil S. Hypertension in women. J Clin Endocrinol Metab 1999; 84(6): 1862–1866.
35. Woods JW. Oral contraceptives and hypertension. Hypertension 1988; 11(3 Pt 2): II11-II15.
36. Dong W, Colhoun HM, Poulter NR. Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994. J Hypertens 1997; 15(10): 1063–1068.
37. Ribstein J, Halimi JM, Du Cailar G et al. Renal characteristics and effect of angiotensin suppression in oral contraceptive users. Hypertension 1999; 33(1): 90–95.
38. Curtis KM, Mohlajee AP, Martins SL et al. Combined oral contraceptive use among women with hypertension: a systematic review. Contraception 2006; 73(2): 179–188.
39. Margolis KL, Adami HO, Luo J et al. A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril 2007; 88(2): 310–316.
40. Chakhtoura Z, Canonico M, Gompel A et al. Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis. J Clin Endocrinol Metab 2011; 96(4): 1169–1174.
41. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. Arch Intern Med 2004; 164(18): 1965–1976.
42. Hussain SF. Progestogen-only pills and high blood pressure: is there an association? A literature review. Contraception 2004; 69(2): 89–97.
43. Lidegaard O, Nielsen LH, Skovlund CW et al. Venous thrombosis in users of nonoral hormonal contraception: follow-up study, Denmark 2001–10. BMJ 2012; 344: e2990. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.e2990>.
44. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. World Health Organization: Geneva 2004. ISBN 92 4 156266 8.
45. Lubianca JN, Moreira LB, Gus M et al. Stopping oral contraceptives: an effective blood pressure-lowering intervention in women with hypertension. J Hum Hypertens 2005; 19(6): 451–455.
46. ACOG Committee on practice bulletin–Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107(6): 1453–1472.
47. Cífková R. Hypertenze v těhotenství. In: Widimský J Jr, Widimský J (eds). Hypertenze. 4th ed. Triton: Praha 2014: 416–434. ISBN 978–80–7387–811–5.
48. Paradisi G, Biaggi A, Savone R et al. Cardiovascular risk factors in healthy women with previous gestational hypertension. J Clin Endocrinol Metab 2006; 91(4): 1233–1238.
49. Rich-Edwards JW, Fraser A, Lawlor DA et al. Pregnancy characteristics and women’s future cardiovascular health: an underused opportunity to improve women’s health? Epidemiol Rev 2014; 36: 57–70.